52
Participants
Start Date
February 5, 2020
Primary Completion Date
July 7, 2023
Study Completion Date
July 7, 2023
Placebo
Participants will receive matching placebo
PF-07209326
Participants will receive SC or IV single ascending doses
PF-07209326
SCD participants will receive a multiple dose of subcutaneous PF-07209326
Columbia University Medical Center - Herbert Irving Pavilion, New York
CUIMC Research Pharmacy, New York
CUMC Research Pharmacy, New York
Howard University College of Medicine, Washington D.C.
Children's Healthcare of Atlanta - Egleston Hospital-Aflac Cancer and Blood Disorders Center, Atlanta
Foundation for Sickle Cell Disease Research, Hollywood
Foundation for Sickle Cell Disease Research, Hollywood
Golisano Children's Hospital of Southwest Florida, Fort Myers
Lee Health - Golisano Children's Hospital of Southwest Florida, Fort Myers
Prism Research LLC dba Nucleus Network, Saint Paul
University of Illinois at Chicago Clinical Research Center, Chicago
University of Illinois at Chicago, Chicago
UT Physicians Comprehensive Sickle Cell Center Houston, Houston
Memorial Hermann clinical research unit, Houston
UT Physicians Comprehensive Sickle Cell Center Houston, Houston
New Haven Clinical Research Unit, New Haven
Lead Sponsor
Pfizer
INDUSTRY